Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

miguelgarfer Oct. 25 at 7:43 PM

$BCAB I've decided to double my position in Bioatla. I'm clear about the situation and have complete confidence. I believe the potential gains versus the potential losses are crystal clear.

0 · Reply

BiotechValues Oct. 25 at 3:30 PM

$BCAB https://x.com/Bullstkpicks/status/1981928904920351140

0 · Reply

onemillion2012 Oct. 25 at 8:00 AM

$BCAB just the beginning

0 · Reply

deni_mimi Oct. 24 at 4:10 PM

$BCAB ..monday bo?

0 · Reply

BiotechValues Oct. 24 at 2:25 PM

$BCAB nice strength today. Seems like some smart money realizing the potential of the EpCAM data upside. Also feels like another day closer to D (ph3 deal) Day.

1 · Reply

SPYmyQQQ Oct. 24 at 2:19 PM

🎯 Target Hit 🏁 📨 From Oct 21, 2025 💊 $BCAB 💵 Entry: $0.6726 ✅ Exit: $0.7868 💰 P/L: +16.98% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

shortkiller7 Oct. 24 at 9:00 AM

$BCAB Compare the difference between the two news! (10/23 vs 9/8) 1. The worldwide market opportunity for 2nd line plus OPSCC is over $1.X billion and for 1st line HPV+ tumors is potentially over $7 billion. 2. The prognosis is currently poor for patients with recurrent/metastatic OPSCC who have previously received standard treatments including surgery, radiation, platinum-based chemotherapy, and PD-1 inhibitor therapy. 3. Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner in early 2026. Waht it means! LO is comming!

2 · Reply

Misterx69 Oct. 23 at 7:49 PM

$BCAB

0 · Reply

pankooo Oct. 23 at 6:06 PM

$BCAB 1Q/2026 TP 3,2 usd

0 · Reply

jjrrjjrr Oct. 23 at 2:57 PM

$BCAB 🤫🤫

0 · Reply

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 5 days ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 22 days ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 6 weeks ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 9, 2025, 2:43 AM EDT - 2 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 2 months ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 3 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 4 months ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 5 months ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 5:55 PM EDT - 6 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 6 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 6 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 6 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 6 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 6 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 6:18 PM EDT - 7 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 5:05 PM EDT - 7 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 7 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 7 months ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 7 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 8 months ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 11 months ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 11 months ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 11 months ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 1 year ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 19, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 7, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Dec 20, 2023, 8:00 AM EST - 2 years ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 2 years ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 6, 2023, 8:00 AM EST - 2 years ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 5, 2023, 8:00 AM EST - 2 years ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

miguelgarfer Oct. 25 at 7:43 PM

$BCAB I've decided to double my position in Bioatla. I'm clear about the situation and have complete confidence. I believe the potential gains versus the potential losses are crystal clear.

0 · Reply

BiotechValues Oct. 25 at 3:30 PM

$BCAB https://x.com/Bullstkpicks/status/1981928904920351140

0 · Reply

onemillion2012 Oct. 25 at 8:00 AM

$BCAB just the beginning

0 · Reply

deni_mimi Oct. 24 at 4:10 PM

$BCAB ..monday bo?

0 · Reply

BiotechValues Oct. 24 at 2:25 PM

$BCAB nice strength today. Seems like some smart money realizing the potential of the EpCAM data upside. Also feels like another day closer to D (ph3 deal) Day.

1 · Reply

SPYmyQQQ Oct. 24 at 2:19 PM

🎯 Target Hit 🏁 📨 From Oct 21, 2025 💊 $BCAB 💵 Entry: $0.6726 ✅ Exit: $0.7868 💰 P/L: +16.98% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

shortkiller7 Oct. 24 at 9:00 AM

2 · Reply

Misterx69 Oct. 23 at 7:49 PM

$BCAB

0 · Reply

pankooo Oct. 23 at 6:06 PM

$BCAB 1Q/2026 TP 3,2 usd

0 · Reply

jjrrjjrr Oct. 23 at 2:57 PM

$BCAB 🤫🤫

0 · Reply

BiotechValues Oct. 23 at 1:57 PM

$BCAB https://ir.bioatla.com/news-releases/news-release-details/bioatla-presents-compelling-mechanistic-rationale-targeting-ror2 Stage getting set for ph3 start. Also guidance remains unchanged regarding timing/partnership (from today's PR)

1 · Reply

shortkiller7 Oct. 23 at 12:48 PM

$BCAB If that mechanism is proven, a first-line treatment in HPV HNSCC challenge is possible. Keytruda combination therapy, so Merck will love it. 7b$ market value...

0 · Reply

shortkiller7 Oct. 23 at 12:17 PM

$BCAB big deal is comming!

0 · Reply

BigPennyStockAlerts Oct. 23 at 12:07 PM

$BCAB BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

0 · Reply

onemillion2012 Oct. 23 at 12:07 PM

$BCAB new poster out. See homepage

0 · Reply

shortkiller7 Oct. 23 at 6:30 AM

$BCAB merck right now!

0 · Reply

winners18 Oct. 22 at 3:45 PM

$BCAB another adc deals

0 · Reply

shortkiller7 Oct. 22 at 12:40 PM

$BCAB odds of BioAtla CAB-ADC (6.5-7/10) Strengths: Safety Advantage: Conditional activation of CAB can reduce normal tissue toxicity (especially gastrointestinal tract). e.g. Grade 3+ TRAEs 49.7% of IBI343 vs. 30% or less of CAB-ADC assumptions. Efficacy Potential: BioAtla's CAB-ADC (ORR 30-40% based on BA3021) is similar ORR expectation in CLDN18.2, low expression patient cover with bystander effect. DIFFERENTIATION: Existing ADCs (e.g., IBI343, AZD0901) are always toxic with active antibodies, and CAB can be positioned as next-generation ADCs with microenvironmental specificity. Market Opportunity: CLDN18.2 Market Expects USD 9.7 Billion In 2030, ADC Advantages Late Line/Monotherapy Over Zolbetuximab (mAb).

0 · Reply

shortkiller7 Oct. 22 at 12:33 PM

$BCAB In conclusion, CAB is a highly suitable technology for addressing the toxicity issue of CLDN18.2 ADC, which, if developed by BioAtla, could have a competitive advantage

0 · Reply

shortkiller7 Oct. 22 at 12:32 PM

$BCAB CLDN18.2 is overexpressed in gastric cancer (60–80%) and pancreatic cancer (50%), but GI toxicity in conventional ADCs is a problem due to limited expression in the normal gastrointestinal tract. CAB can address this issue. Currently, CLDN18.2 ADC (e.g., IBI343, CMG901) reduces toxicity with glycan-based or Fc-silenced designs, but like CAB, environment-dependent activation is more innovative. Although BioAtla has not yet released CLDN18.2 CAB-ADC, it is technically compatible, and BioAtla's platform is being applied to various targets (AXL, ROR2).

0 · Reply

shortkiller7 Oct. 22 at 12:22 PM

$BCAB Another big ADC deal! https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-innovent-signs-114-billion-cancer-therapy-deal-with-japans-takeda-2025-10-22/

0 · Reply

onemillion2012 Oct. 22 at 7:38 AM

$NERV $BCAB can't wait until Bioalta secure capital. For the phase 3 asset. Nerv sold at $2.11 to investors. And now $6. So if Bioalta get a partnership whitout rapping shareholders with new shares Then we get a 300 percent day.

2 · Reply

Market Cap	42.16M
Revenue (ttm)	11.00M
Net Income (ttm)	-69.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.36%
Debt to Equity Ratio	0.00

Volume	1,706,500
Avg Vol	1,132,590
Day's Range	N/A - N/A
Shares Out	58.72M
Stochastic %K	54%
Beta	1.03
Analysts	Sell
Price Target	$10.00